Epi-Informatics
24%
off

Epi-Informatics : Discovery and Development of Small Molecule Epigenetic Drugs and Probes

Free delivery worldwide

Available. Dispatched from the UK in 2 business days
When will my order arrive?

Description

Epi-Informatics: Discovery and Development of Small Molecule Epigenetic Drugs and Probes features multidisciplinary strategies with strong computational approaches that have led to the successful discovery and/or optimization of compounds that act as modulators of epigenetic targets. This book is intended for all those using or wanting to learn more about computational methodologies in epigenetic drug discovery, including molecular modelers, informaticians, pharmaceutical scientists, and medicinal chemists.

With a better understanding of different molecular modeling and cheminformatic approaches, readers can incorporate these techniques into their own drug discovery projects that may involve chemical synthesis and medium- or high-throughput screening. In addition, this book highlights the significance of epigenetic targets to the public health for molecular modelers and chemoinformatians. The goal of this reference is to stimulate ongoing multidisciplinary research and to further improve current computational methodologies and workflows in order to accelerate the discovery and development of epi-drugs and epi-probes.
show more

Product details

  • Paperback | 440 pages
  • 191 x 235 x 27.94mm | 1,210g
  • Academic Press Inc
  • San Diego, United States
  • English
  • colour illustrations
  • 0128028084
  • 9780128028087

Table of contents

Introduction of Epigenetic Targets in Drug Discovery and Current Status of Epi-Drugs and Epi-Probes
Overview of Computer-Aided Drug Design for Epigenetic Targets
Structure-Guided Optimization of DNA Methyltransferase Inhibitors
Discovery and Development of Small Molecules Targeting Epigenetic Enzymes with Computational Methods
Insilico Optimization of the First DNA-Independent Mechanism-Based Inhibitor of Mammalian DNA Methyltransferase DNMT1
Structure-Based Modeling of Histone Deacetylases Inhibitors
Searching Histone Deacetylase Inhibitors under Computational Procedures
Current Development of Protein Arginine Methyltransferase Inhibitor
Molecular Design of Compounds Targeting Histone Methyltransferases
Computational Chemical Biology of Methyllysine Histone Effectors
Structure-Based Design and Computational Studies of Sirtuin Inhibitors
Drug Repurposing for Epigenetic Targets Guided by Computational Methods
Computational Structure-Activity Relationship Studies of Epigenetic Target Inhibitors
Role of Nutrition in Epigenetics and Recent Advances of In Silico Studies
The Road Ahead of the Epi-Informatics Field
show more

About Jose Medina-franco

Dr. Jose Medina-Franco received a Bachelor of Science degree in chemistry from the National Autonomous University of Mexico (UNAM) in 1998. That same year, he joined Procter & Gamble in Mexico City, working in the research and development department. He received a Master of Science degree in 2002 and a Ph.D. degree in 2005, both from the UNAM. In 2005, he joined the University of Arizona as a postdoctoral fellow. Dr. Medina-Franco was named Assistant Member at the Torrey Pines Institute for Molecular Studies in Florida in August 2007. Since then, he has conducted research and academic activities at the Institute of Chemistry, UNAM and Mayo Clinic in Scottsdale. In 2014, he was named Full Time Research Professor of the Pharmacy Department, UNAM where he leads a computational group focused on the discovery and development of epi-drugs. He also serves as an Adjunct Professor at the Florida Atlantic University. Dr. Medina-Franco has more than 8 years of experience working on molecular modeling of DNMT inhibitors. He has lead one of the first research groups applying computational tools for drug discovery of epi-hits. His research group has published several research papers, reviews and book chapters focused on the development of DNMT inhibitors using computational methods. One of the major contributions of his group has been the identification of a distinct DNMT inhibitor with a novel molecular scaffold. The hit compound has been used as a starting point for optimization programs and has served as reference for virtual screening campaigns. Dr. Medina-Franco's group has also initiated a novel computer-guided drug repurposing project.
show more